863 MITTEN ROAD, BURLINGAME, CA
2026 Annual Meeting of Stockholders - Voting Results Announced
Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting
Provides Business Update and Reports First Quarter 2026 Financial Results
Board Appointment - Andrew C. Chan Joins Corvus Pharmaceuticals Board
Corvus Pharmaceuticals Enters Amended Sales Agreement with Jefferies for $200M
Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Corvus Pharmaceuticals Enters Underwriting Agreement for Public Offering
Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Additional Securities
Effectiveness Notice
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Submission Upload
Correspondence